If you would like more information regarding this case, please contact us via or call us toll free at 800.776.6044.
Keller Rohrback Investigates the Inflated Price of Rheumatoid Arthritis Drugs: Enbrel and Humira
Enbrel and Humira are pain management drugs used to treat Rheumatoid Arthritis. The cost of these drugs has increased dramatically and inexplicably over recent years at well over the rate of inflation. For example, the average wholesale price (AWP) of Enbrel jumped from $2,481.79 in July 2012 to $5,330.40 in January 2017—an increase of about 115 percent. Over that same period, Humira increased from $2,458.34 to $5,329.48—an increase of about 117 percent. Patients suffering from Rheumatoid Arthritis have ended up paying thousands of dollars more for their prescriptions.
While drug manufacturers contribute to the price inflation problem, they have not been acting alone. Drug manufacturers maybe colluding with pharmacy benefit managers (PBMs) to raise the “list” prices of drugs—the price consumers pay—thus reaping outsized profits from people who need these drugs to live pain free.
The high cost of these medications, for which no comparable generic forms are currently available, inflicts physical, emotional and financial harm on patients and their families.
Keller Rohrback L.L.P. serves as lead and co-lead counsel in class action lawsuits throughout the country, including actions asserting RICO, ERISA, and consumer claims against PBMs. With offices in New York, Seattle, Phoenix, Ronan, Oakland, and Santa Barbara, our Complex Litigation Group is proud to offer its expertise to clients nationwide. Our trial lawyers have obtained judgments and settlements on behalf of clients in excess of $18 billion.